News

HELIOS-3 is a phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware system.

Clinicians must assume responsibility for this common surgical concern

The topical ophthalmic solution is preservative-free and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.

Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications.

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for improved patient outcomes.

AnnMarie Hipsley, DPT, PhD, explores innovative approaches in ocular biomechanics, shifting focus from lenses to holistic treatments for presbyopia, enhancing vision care.

The acquisition includes product candidates MELT-210, MELT-300, and MELT-400 based on the Zydis ODT (oral dissolving tablet) drug delivery platform.

Inder Paul Singh, MD, discusses groundbreaking findings on the iDose implant's efficacy and safety in glaucoma management during cataract surgery.

CoTx-101 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.

David A. Eichenbaum, MD, FASRS, discusses findings on UBX-1325 for diabetic macular edema, highlighting a shift towards personalized, multi-mechanism therapies.

In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.

Hipsley shares insights into ocular biomechanics and dynamic range of focus, that can help the field to work toward vision restoration and increase eye health.

Research on aflibercept 8 mg reveals promising real-world outcomes for treating wet AMD and diabetic macular edema, enhancing vision and safety.

STAAR Surgical extends its merger timeline with Alcon, inviting third-party proposals to maximize stockholder value amid ongoing opposition from Broadwood Partners.

Discover how RGB technology enhances eye disease diagnosis, improving accuracy and efficiency in clinical practice with advanced imaging techniques.

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes in retina surgery.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.